MYLK and neoplasm: It was found that when KRP-DOX was combined with doxorubicin, it had multiple synergistic functions in vitro and in vivo, including good biocompatibility and biodistribution, selective accumulation of tumor tissues, and an ability to remain in tumor tissues and be internalized by cancer cells in the presence of KRP.